Lidocaine HCl Viscous (Lidocaine HCl) Patent Expiration, LOE Window & CMS Spending

Lidocaine HCl Viscous (Lidocaine HCl) by Hikma Pharmaceuticals: Off-Patent Genericized (AB Competition), 8 AB generics, $14.1M 2024 CMS Part D & Medicaid spend, and $1,994 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHikma Pharmaceuticals
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$14.1M
2024 Medicare Part D Spend$6.3M
2024 Medicaid Spend$7.9M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,994 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Hikma Pharmaceuticals across sibling Meru public-data platforms.